more than half of the 26 women from the trial were

more than half of the 26 women from the trial were still alive

should be worldwide news right there...

and this is what perplexes me - 2021 - slightly better OS than trodelvy, but can we assume better safety profile? and why cant there be multiple drugs on the market for this when there are multiple drugs on the market for every other ailment known to man? those results in 2021 sealed my faith in LL, and sealed my disdain for the entire process as LL was delayed denied and demoted...what is it going to take to get this drug on the market? does it have to exceed current drugs OS by a multiple of 2x, 3x, 4x before it is taken seriously? because it feels like thats about to happen...

in the meantime any friends or family get diagnosed with mTNBC i better be able to get right to try, these OS numbers are astounding (true numbers we have really been notified of yet)

Quote:

---

On the other hand, Gilead's Trodelvy, the other leading FDA approved treatment for mTNBC, wasn't involved in the aforementioned MD Anderson study, but was the drug that the FDA cited to deny LL breakthrough designation status when CYDY announced LL's mTNBC phase 2 clinical trial results in August and November, 2021. Back then, LL produced a OS (overall survival) endpoint that although only slightly better than Trodelvy's, was still ongoing because more than half of the 26 women from the trial were still alive.

---